Initiation of prostate cancer in mice by Tp53R270H: Evidence for an alternative molecular progression

DMM Disease Models and Mechanisms

Volumn 5, Issue 6, 2012, Pages 914-920

  Vinall, Ruth L ^a,b,c   Chen, Jane Q ^b   Hubbard, Neil E ^b   Sulaimon, Shola S ^b   Shen, Michael M ^d   DeVere White, Ralph W ^b,c   Borowsky, Alexander D ^b,c  

^a CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; PROTEIN KINASE B; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENOTYPE; IMMUNOPHENOTYPING; INVASIVE CARCINOMA; KNOCKOUT MOUSE; MALE; MISSENSE MUTATION; MOUSE; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION;

AMINO ACID SUBSTITUTION; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HETEROZYGOTE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOPHENOTYPING; INTEGRASES; MALE; MICE; MICE, MUTANT STRAINS; ORGAN SPECIFICITY; PRECANCEROUS CONDITIONS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84870007145     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.008995     Document Type: Article

References (35)

1. Acevedo, V. D., Gangula, R. D., Freeman, K. W., Li, R., Zhang, Y., Wang, F., Ayala, G. E., Peterson, L. E., Ittmann, M. and Spencer, D. M. (2007). Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12, 559-571. (Pubitemid 350199071)
2. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Moul, J. W. (1996). Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol. 156, 1511-1516. (Pubitemid 26307649)
3. Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., Kim, M., Desai, N., Young, P., Norton, C. R., Gridley, T., Cardiff, R. D., Cunha, G. R. et al. (1999). Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13, 966-977. (Pubitemid 29200980)
4. Byrne, R. L., Horne, C. H., Robinson, M. C., Autzen, P., Apakama, I., Bishop, R. I., Neal, D. E. and Hamdy, F. C. (1997). The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br. J. Urol. 79, 190-195.
5. Chi, S. G., deVere White, R. W., Meyers, F. J., Siders, D. B., Lee, F. and Gumerlock, P. H. (1994). p53 in prostate cancer: frequent expressed transition mutations. J. Natl. Cancer Inst. 86, 926-933. (Pubitemid 24177307)
6. Chiaverotti, T., Couto, S. S., Donjacour, A., Mao, J. H., Nagase, H., Cardiff, R. D., Cunha, G. R. and Balmain, A. (2008). Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am. J. Pathol. 172, 236-246. (Pubitemid 351186384)
7. de Vries, A., Flores, E. R., Miranda, B., Hsieh, H. M., van Oostrom, C. T., Sage, J. and Jacks, T. (2002). Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl. Acad. Sci. USA 99, 2948-2953. (Pubitemid 34240566)
8. Downing, S. R., Jackson, P. and Russell, P. J. (2001). Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence. Urol. Oncol. 6, 103-110. (Pubitemid 32409995)
9. Downing, S. R., Russell, P. J. and Jackson, P. (2003). Alterations of p53 are common in early stage prostate cancer. Can. J. Urol. 10, 1924-1933.
10. Elgavish, A., Wood, P. A., Pinkert, C. A., Eltoum, I. E., Cartee, T., Wilbanks, J., Mentor-Marcel, R., Tian, L. and Scroggins, S. E. (2004). Transgenic mouse with human mutant p53 expression in the prostate epithelium. Prostate 61, 26-34. (Pubitemid 39099307)
11. Gonzalgo, M. L. and Isaacs, W. B. (2003). Molecular pathways to prostate cancer. J. Urol. 170, 2444-2452. (Pubitemid 37414032)
12. Heidenberg, H. B., Sesterhenn, I. A., Gaddipati, J. P., Weghorst, C. M., Buzard, G. S., Moul, J. W. and Srivastava, S. (1995). Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 154, 414-421.
13. Hughes, J. H., Cohen, M. B. and Robinson, R. A. (1995). p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma. Mod. Pathol. 8, 462-466.
14. Jeet, V., Russell, P. J. and Khatri, A. (2010). Modeling prostate cancer: a perspective on transgenic mouse models. Cancer Metastasis Rev. 29, 123-142.
15. Lin, Y., Liu, G., Zhang, Y., Hu, Y. P., Yu, K., Lin, C., McKeehan, K., Xuan, J. W., Ornitz, D. M., Shen, M. M. et al. (2007). Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development 134, 723-734. (Pubitemid 46437914)
16. Masumori, N., Thomas, T. Z., Chaurand, P., Case, T., Paul, M., Kasper, S., Caprioli, R. M., Tsukamoto, T., Shappell, S. B. and Matusik, R. J. (2001). A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 61, 2239-2249. (Pubitemid 32692054)
17. Meyers, F. J., Gumerlock, P. H., Chi, S. G., Borchers, H., Deitch, A. D. and deVere White, R. W. (1998). Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 83, 2534-2539. (Pubitemid 29019574)
18. Moul, J. W., Bettencourt, M. C., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Bauer, J. J. (1996). Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 120, 159-166; discussion 166-167.
19. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C. and Conti, C. J. (1993). p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. 85, 1657-1669.
20. Nesslinger, N. J., Shi, X. B. and deVere White, R. W. (2003). Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res. 63, 2228-2233. (Pubitemid 36538631)
21. Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D. and Jacks, T. (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860. (Pubitemid 40017690)
22. Olivier, M., Petitjean, A., Marcel, V., Petre, A., Mounawar, M., Plymoth, A., de Fromentel, C. C. and Hainaut, P. (2009). Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 16, 1-12.
23. Park, J. H., Walls, J. E., Galvez, J. J., Kim, M., Abate-Shen, C., Shen, M. M. and Cardiff, R. D. (2002). Prostatic intraepithelial neoplasia in genetically engineered mice. Am. J. Pathol. 161, 727-735. (Pubitemid 36142181)
24. Prendergast, N. J., Atkins, M. R., Schatte, E. C., Paulson, D. F. and Walther, P. J. (1996). p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J. Urol. 155, 1685-1692. (Pubitemid 26126976)
25. Robles, A. I. and Harris, C. C. (2010). Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb. Perspect. Biol. 2, a001016.
26. Schlechte, H., Lenk, S. V., Loning, T., Schnorr, D., Rudolph, B. D., Ditscherlein, G. and Loening, S. A. (1998). p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer. Eur. Urol. 34, 433-440. (Pubitemid 28499728)
27. Shen, M. M. and Abate-Shen, C. (2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24, 1967-2000.
28. Shi, X. B., Di Mauro, S. M., Highshaw, R., Deitch, A. D., Evans, C. P., Gumerlock, P. H. and deVere White, R. W. (2002). Application of a yeast assay to detect functional p53 mutations in archival prostate cancer tissue. Cancer Biother. Radiopharm. 17, 657-664. (Pubitemid 36025947)
29. Soussi, T. (2007). p53 alterations in human cancer: more questions than answers. Oncogene 26, 2145-2156.
30. Takahashi, T., Munakata, M., Ohtsuka, Y., Nisihara, H., Nasuhara, Y., Kamachi-Satoh, A., Dosaka-Akita, H., Homma, Y. and Kawakami, Y. (2002). Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis. Cancer 95, 624-633. (Pubitemid 34810189)
31. Thomsen, M. K., Butler, C. M., Shen, M. M. and Swain, A. (2008). Sox9 is required for prostate development. Dev. Biol. 316, 302-311.
32. Tomkova, K., Tomka, M. and Zajac, V. (2008). Contribution of p53, p63, and p73 to the developmental diseases and cancer. Neoplasma 55, 177-181.
33. Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D. et al. (2004). Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387. (Pubitemid 38482073)
34. Vinall, R. L., Tepper, C. G., Shi, X. B., Xue, L. A., Gandour-Edwards, R. and deVere White, R. W. (2006). The R273H p53 mutation can facilitate the androgenindependent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 25, 2082-2093.
35. Wijnhoven, S. W., Zwart, E., Speksnijder, E. N., Beems, R. B., Olive, K. P., Tuveson, D. A., Jonkers, J., Schaap, M. M., van den Berg, J., Jacks, T. et al. (2005). Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res. 65, 8166-8173. (Pubitemid 41330580)